Tickers

1. Composite Trajectory Verdict

All three statements carry roughly equal weight for a broadline foodservice distributor: the income statement shows operating leverage, the cash flow statement reveals the capital intensity and shareholder-return choices, and the balance sheet captures the leverage those choices create.

Composite Trajectory: Mixed

Earnings are clearly improving — revenue, gross profit, operating income, and net income all rose year-over-year in both the latest annual and quarterly periods, with margins expanding at each level. Cash generation is mixed: full-year 2025 free cash flow jumped 15% to $965M, but first-half 2026 free cash flow fell 3% to $552M despite higher net income, and operating cash flow was flat at $725M. The balance sheet is deteriorating in leverage terms: total debt rose from $4.93B to $5.24B while shareholders' equity fell from $4.53B to $4.31B (and further in H1 2026) due to share repurchases that exceeded net income in each period.

2. Red Flags

• Share repurchases exceed net income: FY2025 repurchased $926M of stock vs. $676M net income (10-K FY2025, Consolidated Statements of Cash Flows); H1 2026 repurchased $445M vs. $391M net income (10-Q Q2 2026, MD&A Financing Activities).
• Equity declining while debt rises: Shareholders' equity dropped from $4.53B to $4.31B (Dec 2024 to Dec 2025) and total debt rose from $4.93B to $5.20B (10-K FY2025, Consolidated Balance Sheets); by June 2026 debt reached $5.24B (10-Q Q2 2026, Indebtedness table).
• Free cash flow declined in H1 2026 despite higher earnings: H1 2026 FCF $552M vs. $569M in H1 2025 (10-Q Q2 2026, Non-GAAP Reconciliations), with operating cash flow flat at $725M both periods (10-Q Q2 2026, Cash Flows table).
• Pension settlement charge recurs in adjusted metrics: The $124M pension settlement loss in FY2024 (10-K FY2025, Results of Operations) is excluded from Adjusted EBITDA/Adjusted Net Income, but similar "business transformation costs" ($48M FY2025, $39M FY2024, $28M FY2023) and "acquisition/integration costs" ($32M FY2025, $22M FY2024) appear annually (10-K FY2025, Non-GAAP Reconciliations).
• LIFO volatility materially affects gross profit comparability: FY2025 LIFO expense $65M vs. $61M FY2024 (10-K FY2025, Gross Profit); Q2 2026 LIFO benefit $5M vs. $14M expense in Q2 2025 (10-Q Q2 2026, Gross Profit); H1 2026 LIFO expense $33M vs. $19M H1 2025 (10-Q Q2 2026, Gross Profit).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Overall Assessment: Net sales grew 4.1% to $39.4B in FY2025 (10-K FY2025, Consolidated Statements of Operations) and 4.5% to $10.5B in Q2 2026 (10-Q Q2 2026, Results of Operations). Gross margin expanded from 17.3% to 17.4% annually and from 17.6% to 18.2% in Q2 (same sources). Operating margin improved from 2.9% to 3.0% annually and from 3.7% to 4.2% in Q2. Net income rose 37% to $676M in FY2025 (helped by absence of the FY2024 $124M pension settlement) and 23% to $275M in Q2 2026. Diluted EPS increased from $2.02 to $2.94 annually and from $2.02 to $2.94 in Q2 (10-K FY2025, Consolidated Statements of Operations; 10-Q Q2 2026, Results of Operations). The trajectory is consistently positive across annual and quarterly GAAP figures.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Overall Assessment: Full-year operating cash flow rose 17% to $1.37B in FY2025 (10-K FY2025, Consolidated Statements of Cash Flows) and free cash flow (non-GAAP) rose 15% to $965M (10-K FY2025, Non-GAAP Reconciliations). However, first-half 2026 operating cash flow was flat at $725M vs. H1 2025 (10-Q Q2 2026, Cash Flows table) despite 15% higher net income ($391M vs. $339M), and free cash flow fell 3% to $552M (10-Q Q2 2026, Non-GAAP Reconciliations). Capital expenditures increased to $174M in H1 2026 from $161M (same source). The divergence between rising earnings and flat/declining cash conversion in the most recent interim period tempers the annual improvement.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Overall Assessment: Total debt increased from $4.93B (Dec 2024) to $5.20B (Dec 2025) to $5.24B (June 2026) (10-K FY2025, Indebtedness table; 10-Q Q2 2026, Indebtedness table). Shareholders' equity fell from $4.53B to $4.31B over FY2025 (10-K FY2025, Consolidated Balance Sheets) driven by $926M of share repurchases (10-K FY2025, Consolidated Statements of Cash Flows) and continued to decline in H1 2026 with an additional $445M of buybacks (10-Q Q2 2026, MD&A Financing Activities). Current assets rose to $4.45B from $4.16B (10-Q Q2 2026, Consolidated Balance Sheets; 10-K FY2025, Consolidated Balance Sheets) but current liabilities also increased. Cash remains low ($41M-$56M) though ABL Facility availability is ample ($1.56B Dec 2025, $1.75B June 2026). The combination of rising leverage and shrinking equity base indicates balance sheet deterioration.

6. Data Gaps

• Q1 2026 and Q3 2025 standalone quarterly income statement figures (the 10-Qs for those periods were provided but their detailed income statement tables were truncated in the filing text; only the Q2 2026 10-Q contains a full Results of Operations table).
• Full quarterly cash flow statements for Q1 2026 and Q3 2025 (only H1 2026 and H1 2025 are shown in the Q2 2026 10-Q).
• Quarterly balance sheets for Q1 2026 and Q3 2025 (only June 27, 2026 and Dec 27, 2025 are shown in the Q2 2026 10-Q).
• Interest coverage ratio and debt/EBITDA covenant metrics (not explicitly disclosed in the provided excerpts).
• Organic case volume trends for quarters prior to Q2 2026 (only Q2 2026 and Q2 2025 organic figures are in the Q2 2026 10-Q Highlights).